Maky Zanganeh
About Maky Zanganeh
Maky Zanganeh is co-CEO of Summit Therapeutics, a small, publicly traded biotech firm with no revenue.
Shares of Summit Therapeutics have surged in 2024 due to clinical trial data released in September that showed its experimental cancer drug outperformed Merck's blockbuster Keytruda.
Zanganeh, who owns about 5% of Summit's stock, previously worked as chief operating officer at drug developer Pharmacyclics, which AbbVie acquired for $21 billion in 2015.
Zanganeh runs Summit Therapeutics as co-CEO with Robert (Bob) Duggan, who became a billionaire after investing in and running Pharmacyclics.
Zanganeh, originally from Iran, got a degree in dentistry at a university in France, then joined robotic surgery firm Computer Motion and moved to the U.S. to serve a vice president for the firm.
Personal stats
Citizenship
United States of AmericaSource of wealth
biotechResidence
Atherton, CaliforniaMarital status
SingleBirth date
09/13/70 (age 54)Number of children
1Education
Master of Business Administration, Schiller International University; DDS, University of StrasbourgSelf-made
self-madeMaky Zanganeh’s fortune is worth
troy ounces of gold
median U.S. household
median U.S. income
U.S. credit card volume
GDP of the United States
United States debt
Related people
Did you know?
Zanganeh is a cancer survivor; she was diagnosed with breast cancer in 2020, and has since recovered.
Net worth over time
Real-time ranking
Financial assets
NYSE | ABBV-US
AbbVie Inc.NASDAQ | PLSE-US
Pulse BioSciencesNASDAQ | PLSE-US
Pulse BioSciencesNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsNASDAQ | SMMT-US
Summit TherapeuticsImages © Forbes.com. All rights reserved.